Through the activation of AMPK, metformin suppresses the proliferation and clonogenic activity of several chronic myeloid leukemia (CML) lines, such as those that are imatinib-resistant and T315I BCR-ABL mutants 152. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.